Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces the FDA clearance of the pocket-sized PICO◊ system, a single use Negative Pressure Wound Therapy (NPWT) system. PICO is cleared for use both in a hospital and homecare setting and expands the use of NPWT from the traditional wound care population to include a wider range of patients undergoing orthopaedic surgery, plastic surgery and general surgical procedures. This FDA clearance follows the recent successful launch of PICO in Europe, Canada, and Australia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51011-smith-nephew-pico-system-fda-approval-npwt
On May 27, CVS/pharmacy launched a new in-store fundraising campaign named Advancing Medical Research, to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS) and cystic fibrosis (CF). Funds raised through the campaign will benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research, and the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis. Supporters for the 2012 campaign can donate $1 or $3 dollars at the register in CVS/pharmacy locations and online at www.cvs.com/alscff through June 30.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56330-cvs-pharmacy-fundraising-campaign-support-als-and-cystic-fibrosis
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
http://adultadhdtreatmentblog.com/adhd-alternative-treatment/
In recent years, study has brought to light some fairly startling details about using prescription medications to treat ADHD. For this reason, along with other people, many parents are now looking for ADHD alternative treatments for their children. Things like potentially serious side results, unknown long term effects and the increasing expenses of doctor prescribed medications are making an ADHD alternative therapy seem like a better idea each day. In this article, we
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, is simplifying the design, fitting and care of full-face masks for sleep apnea patients. With its unique modular design, the new Amara full-face mask further demonstrates Philips’ commitment to developing solutions aimed at improving care and outcomes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57117-philips-respironics-revolutionary-full-face-mask-sleep-therapy
